Current Report Filing (8-k)
December 18 2017 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 12, 2017
PRESSURE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Massachusetts
|
|
001-38185
|
|
04-2652826
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
14
Norfolk Avenue
South
Easton, Massachusetts 02375
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (508) 230-1828
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01 Entry into a Material Definitive Agreement.
Acquisition
of All Assets of BaroFold, Inc.
On
December 12, 2017, Pressure BioSciences, Inc. (the “Company”) and BaroFold, Inc. (“BaroFold”)
signed an Asset Purchase Agreement (the “Agreement”) for the Company to acquire all of BaroFold’s assets.
The acquisition closed on December 12
th
with the Company’s issuance of one hundred fifty thousand (150,000) restricted
shares of the Company’s common stock to BaroFold and with the transfer of all of BaroFold’s assets to
the Company. Following the closing, the Company is to pay, by December 29, 2017, $150,000 as part of the purchase price of the
assets. Among the assets acquired were all patents, equipment, and intellectual property relating to BaroFold’s PreEMT
high-pressure protein refolding technology.
The
foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by the complete
text of the document attached as Exhibit 10.1 to this Current Report on Form 8-K.
Item
3.02 Unregistered Sales of Equity Securities.
The
information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
The
issuance of the securities described in Item 1.01 was completed in accordance with the exemption from registration provided by
Section 4(a)(2) of the Securities Act of 1933, as amended. The Company’s reliance upon Section 4(a)(2) of the Securities
Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private
transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous
public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; and (e)
the negotiations for the issuance of the securities took place directly between BaroFold and the Company.
Item
8.01 Other Events.
On
December 13, 2017, the Company issued a press release announcing the acquisition of all of BaroFold’s assets.
A
copy of the press release of the Company is included as Exhibit 99.1 of this Report and is incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
*
We have omitted certain schedules to this agreement in accordance with Item 601(b)(2) of Regulation S-K, and we will supplementally
furnish a copy of any omitted schedule to the Securities and Exchange Commission upon request.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
Dated:
December 18, 2017
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher
|
|
|
President
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From May 2023 to May 2024